Skip to main content

Advertisement

SpringerLink
Log in

When shouldCandida isolates be tested for susceptibility to azole antifungal agents?

  • Editorial
  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Denning D, Baily GG, Hood SV: Azole resistance inCandida. European Journal of Clinical Microbiology & Infectious Diseases, 1997, 4: 261–280.

    Google Scholar 

  2. National Committee for Clinical Laboratory Standards: Reference method for broth dilution antifungal susceptibility testing of yeasts. Tentative standard M27-T. NCCLS, Wayne, PA, 1995.

    Google Scholar 

  3. Bille J: Correlation between in vitro and in vivo activity of antifungal agents against yeasts. Journal of Medical Mycology, 1996, 6: 118–122.

    Google Scholar 

  4. Rex JH, Rinaldi MG, Pfaller MA: Resistance ofCandida species to fluconazole. Antimicrobial Agents and Chemotherapy 1995, 39: 1–8.

    PubMed  Google Scholar 

  5. Sanglard D, Kuchler K, Ischer F, Pagani JL, Monod M, Bille J: Mechanisms of resistance to azole antifungal agents inCandida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrobial Agents and Chemotherapy 1995, 39: 2378–2386.

    PubMed  Google Scholar 

  6. Lacassin F, Damond F, Chochillon C, Longuet P, Lebras J, Vilde JL, Leport C: Response to fluconazole by 23 patients with human immunodeficiency virus infection and oral candidiasis: pharmacological and mycological factors. Antimicrobial Agents and Chemotherapy 1996, 40: 1961–1963.

    PubMed  Google Scholar 

  7. Rex J, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A, Ghannoum MA, Lancaster M, Odds FC, Rinaldi MG, Walsh TJ, Barry A: Development of interpretive breakpoints for antifungal susceptibility testing; conceptual framework and analysis of in vitro and in vivo correlation data for fluconazole and itraconazole andCandida infections. Clinical Infectious Diseases 1997, 24: 235–247.

    PubMed  Google Scholar 

  8. van't Wout JW: Fluconazole treatment of candidal infections caused by non-albicansCandida species. European Journal of Clinical Microbiology & Infectious Diseases 1996, 15: 238–242.

    Google Scholar 

  9. Rex JH, Pfaller MA, Barry AL, Nelson PW, Webb CD, and the NIAID Mycosis Study Group and the Candidemia Study Group: Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. Antimicrobial Agents and Chemotherapy 1995, 39: 40–44.

    PubMed  Google Scholar 

  10. Barry AL, Brown SD: Fluconazole disk diffusion procedure for determining susceptibility ofCandida species. Journal of Clinical Microbiology 1996, 34: 2154–2157.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut de Microbiologie, Centre Hospitalier Universitaire Vaudois, Rue du Bugnon 44, 1011, Lausanne, Switzerland

    J. Bille

Authors
  1. J. Bille
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bille, J. When shouldCandida isolates be tested for susceptibility to azole antifungal agents?. Eur. J. Clin. Microbiol. Infect. Dis. 16, 281–282 (1997). https://doi.org/10.1007/BF01695631

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01695631

Search

Navigation